| P50 | author | Gianfranco Amicosante | Q56989430 |
| P2093 | author name string | Amicosante G | |
| | Belloni R | |
| | Bianchi C | |
| | Lombardi G | |
| | Luzzaro F | |
| | Perilli M | |
| | Toniolo A | |
| | Zollo A | |
| P2860 | cites work | beta-Lactamases in laboratory and clinical resistance | Q24669605 |
| | Inhibitor-resistant TEM beta-lactamases: phenotypic, genetic and biochemical characteristics | Q33647947 |
| | A novel extended-spectrum TEM-type beta-lactamase (TEM-52) associated with decreased susceptibility to moxalactam in Klebsiella pneumoniae | Q33690561 |
| | beta-Lactamases responsible for resistance to expanded-spectrum cephalosporins in Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis isolates recovered in South Africa. | Q33693251 |
| | Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens | Q34708485 |
| | New variant of TEM-10 beta-lactamase gene produced by a clinical isolate of proteus mirabilis | Q35114864 |
| | beta-Lactam resistance in gram-negative bacteria: global trends and clinical impact | Q35535598 |
| | Resistance to cefotaxime and seven other beta-lactams in members of the family Enterobacteriaceae: a 3-year survey in France | Q35893975 |
| | TEM-24 produced by four different species of Enterobacteriaceae, including Providencia rettgeri, in a single patient | Q39471585 |
| | Diversity of TEM mutants in Proteus mirabilis | Q39472171 |
| | Piperacillin/tazobactam: a critical review of the evolving clinical literature | Q41125741 |
| | Direct sequencing of the amplified structural gene and promoter for the extended-broad-spectrum beta-lactamase TEM-9 (RHH-1) of Klebsiella pneumoniae | Q42631764 |
| | Antimicrobial resistance in Enterobacteriaceae in Brooklyn, NY: epidemiology and relation to antibiotic usage patterns. | Q54049533 |
| | Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers a reevaluation after five years | Q54179293 |
| | Extended-spectrum beta-lactamase in Proteus mirabilis. | Q54206520 |
| | Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. | Q54380570 |
| | Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections | Q54568073 |
| | Evaluation of clonal relatedness of extended-spectrum beta-lactamase-producing Proteus mirabilis isolates by quantitative antibiogram and RAPD typing. | Q54570947 |
| | Characterization of an inhibitor-resistant enzyme IRT-2 derived from TEM-2 beta-lactamase produced by Proteus mirabilis strains. | Q54583766 |
| | National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers | Q54616485 |
| | Escherichia coli and Klebsiella pneumoniae strains more susceptible to cefoxitin than to third generation cephalosporins | Q70275486 |
| | Clinical relevance of Proteus mirabilis in hospital patients: a two year survey | Q73626122 |
| | Permeability to carbapenems of Proteus mirabilis mutants selected for resistance to imipenem or other beta-lactams | Q73807225 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Proteus mirabilis | Q311273 |
| | multiple drug resistance | Q643839 |
| P304 | page(s) | 131-135 | |
| P577 | publication date | 2001-02-01 | |
| P1433 | published in | International Journal of Antimicrobial Agents | Q15724616 |
| P1476 | title | Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations | |
| P478 | volume | 17 | |